Board member

Ruth Loos is a Vice Executive Director and Group Leader of the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) and professor at the University of Copenhagen. She is also a part-time professor at the Icahn School of Medicine at Mount Sinai in New York. She has been a Board Member of the European Association for the Study of Diabetes (EASD) since 2022 and of the BioMed Alliance since 2024. She is also a trustee of European Diabetology since 2022.

Dr. Loos’ research focuses on the etiology of obesity and the identification of genes and genetic loci that contribute to the risk of obesity and related traits. Her group studies refined adiposity phenotypes and biomarkers to target the deeper layers that define “obesity”. As a founding member of the GIANT (Genetic Investigation of ANTropometric traits) consortium, she has spearheaded many of the large-scale gene-discovery efforts. As more and more genetic variants are discovered, professor Loos examines whether genotype information can be used to identify subtypes of obesity, predict who is at risk of becoming obese, or prescribe tailored prevention and treatment strategies in the context of precision diagnosis, prevention, and treatment.

Dr. Loos has published over 550 articles in peer-reviewed journals and several book chapters [H index (June 2024): 168].